Disclaimer

The website is targeted at investors qualifying as professional investors under MiFID (Directive 2004/39/EU) only. Retail investors are therefore kindly asked to leave this website.

The website and its content is not intended for US Persons, who are kindly asked to leave the website as well.

The content of the website is for information purposes only. The information does not constitute, and shall not be considered as, an offer or invitation to purchase or sell any of the products or services mentioned on the website. The information, calculations etc. on the website shall not be considered investment advice or requests to engage in investment operations.

All reasonable precautions have been taken to ensure the correctness and accuracy of the information available through the website. However, the correctness and accuracy is not guaranteed and C WorldWide Management Fondsmaeglerselskab A/S accepts no liability for any errors, spelling mistakes or omissions. Neither is C WorldWide Management Fondsmaeglerselskab A/S responsible for the suitability of the information on or the content of the website. The information on the website may be amended by C WorldWide Management Fondsmaeglerselskab A/S at any time without notice.

The website and its content has been prepared in accordance with Danish law and the information provided may not satisfy the laws of any other country.

Past performance is not a reliable indicator of future performance.

By accepting, I confirm that I am a professional investor, and that I have understood the terms of use.

Leave
Accept
ⓒ C WORLDWIDE ASSET MANAGEMENT FONDSMAEGLERSELSKAB A/S | DAMPFAERGEVEJ 26 | DK-2100 COPENHAGEN | CVR: 78 42 05 10
Fakta

C WORLDWIDE MEDICAL SMALL & MID CAP AS OF 31 MAY 2017

NET OF FEES IN EUR

STRATEGY

The investment objective of the C WorldWide Medical Small & Mid Cap fund is to seek capital appreciation by investing exclusively in equities of companies in biotechnology, healthcare services, medical technology and pharmaceuticals. An investment in the strategy gives exposure to an interesting, but complex arena characterized by new scientific discoveries and strong growth.

INVESTMENT RETURNS

5C7452 C WorldWide Medical Small & Mid Cap 065696 Benchmark

TOP 10 HOLDINGS

Share in %
Exact Sciences 4.1 %
Aerie Pharmaceuticals 3.6 %
Coherus Biosciences 3.6 %
Insulet 3.4 %
Kite Pharma 3.4 %
Glaukos 3.4 %
Novadaq Technologies 3.3 %
K2M Group 3.2 %
Intersect ENT 3.2 %
Aimmune Therapeutics 3.2 %

RETURN & RISK

1 Y 3 Y 5 Y 10 Y Lifetime P.A.
C WorldWide Medical Small & Mid Cap (%) 12.1 15.0 15.8 6.6 15.5 15.5
Benchmark (%) 14.2 17.9 19.1 12.1 10.5 10.5
Relative performance (%) -2.1 -2.9 -3.3 -5.5 5.0 5.0
3 Y 5 Y 10 Y Lifetime P.A.
Std. dev. portfolio (%) 31.3 27.7 25.9 29.6 29.6
Std. dev. benchmark (%) 25.3 23.2 22.0 27.4 27.4
Beta 1.2 1.1 1.1 0.9 0.9

GEOGRAPHIC DIVERSIFICATION

SECTOR EXPOSURE

FACTS

Security identifier (ISIN): LU0091821107
Launch date: 3 August 1998
Management fee: 1.70% per annum
Dealing frequency: Daily
Base currency: EUR
Minimum investment: EUR 1,000
Benchmark: Russell® 2000 Healthcare
NAV at month end: 303.96
Fund AUM: 97.1 million
Investment Manager: C WorldWide Asset Management, Stockholm
Portfolio Manager: Mikael Svensson

DISCLAIMER

The fact sheet is for information purposes only. The fact sheet does not constitute, and shall not be considered as, an offer or invitation to purchase or sell any fund. The information, calculations etc. shall not be considered investment advice or requests to engage in investment operations.

All reasonable precautions have been taken to ensure the correctness and accuracy of the fact sheet. However, the correctness and accuracy is not guaranteed and C WorldWide Asset Management Fondsmaeglerselskab A/S accepts no liability for any errors, spelling mistakes or omissions.

It is emphasized that the figures in the fact sheet are historical, and that past performance is no reliable indicator of future performance.